Adaptive servoventilation improves cardiac function and respiratory stability

Clin Res Cardiol. 2011 Feb;100(2):107-15. doi: 10.1007/s00392-010-0216-9. Epub 2010 Sep 12.


Cheyne-Stokes respiration (CSR) in patients with chronic heart failure (CHF) is of major prognostic impact and expresses respiratory instability. Other parameters are daytime pCO₂, VE/VCO₂-slope during exercise, exertional oscillatory ventilation (EOV), and increased sensitivity of central CO₂ receptors. Adaptive servoventilation (ASV) was introduced to specifically treat CSR in CHF. Aim of this study was to investigate ASV effects on CSR, cardiac function, and respiratory stability. A total of 105 patients with CHF (NYHA ≥ II, left ventricular ejection fraction (EF) ≤ 40%) and CSR (apnoea-hypopnoea index ≥ 15/h) met inclusion criteria. According to adherence to ASV treatment (follow-up of 6.7 ± 3.2 months) this group was divided into controls (rejection of ASV treatment or usage <50% of nights possible and/or <4 h/night; n = 59) and ASV (n = 56) adhered patients. In the ASV group, ventilator therapy was able to effectively treat CSR. In contrast to controls, NYHA class, EF, oxygen uptake, 6-min walking distance, and NT-proBNP improved significantly. Moreover, exclusively in these patients pCO₂, VE/VCO₂-slope during exercise, EOV, and central CO₂ receptor sensitivity improved. In CHF patients with CSR, ASV might be able to improve parameters of SDB, cardiac function, and respiratory stability.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Cheyne-Stokes Respiration / complications*
  • Cheyne-Stokes Respiration / diagnosis
  • Cheyne-Stokes Respiration / rehabilitation*
  • Chronic Disease
  • Feedback
  • Female
  • Heart Failure / complications*
  • Heart Failure / diagnosis
  • Heart Failure / rehabilitation*
  • Humans
  • Male
  • Middle Aged
  • Respiration, Artificial / methods*
  • Treatment Outcome